Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - dicloxacillin sodium, quantity: 543.682 mg - capsule - excipient ingredients: magnesium stearate; silicon dioxide; gelatin; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin.,dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin.

United States - English - NLM (National Library of Medicine)

claris lifesciences, inc. - nafcillin sodium (unii: 49g3001bck) (nafcillin - unii:4cnz27m7rv) - nafcillin 1 g - nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see clinical pharmacology - susceptibility tests ). nafcillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. nafcillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus , therapy should not be continued with nafcillin for injection, usp. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nafcillin for injection and other antibacterial drugs, nafcillin for injection should be used only to treat or prevent infections that are proven or strongly sus

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

orion pharma (my) sdn. bhd. - warfarin sodium -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

orion pharma (my) sdn. bhd. - warfarin sodium -

United States - English - NLM (National Library of Medicine)

truemed group llc - dicloxacillin (unii: cof19h7wbk) (dicloxacillin - unii:cof19h7wbk) -

Canada - English - Health Canada

teva canada limited - cephalexin (cephalexin monohydrate) - capsule - 250mg - cephalexin (cephalexin monohydrate) 250mg - first generation cephalosporins

Canada - English - Health Canada

teva canada limited - cephalexin (cephalexin monohydrate) - capsule - 500mg - cephalexin (cephalexin monohydrate) 500mg - first generation cephalosporins

Canada - English - Health Canada

teva canada limited - cephalexin (cephalexin monohydrate) - powder for suspension - 250mg - cephalexin (cephalexin monohydrate) 250mg - first generation cephalosporins

Canada - English - Health Canada

teva canada limited - cephalexin (cephalexin monohydrate) - powder for suspension - 125mg - cephalexin (cephalexin monohydrate) 125mg - first generation cephalosporins

Canada - English - Health Canada

teva canada limited - cephalexin (cephalexin monohydrate) - tablet - 250mg - cephalexin (cephalexin monohydrate) 250mg - first generation cephalosporins